Home/Recalls/FDA-D-0292-2026
FDA DrugsClass II

Rosuvastatin Tablets, USP, 10 mg, Rx Only, 50 Tablets (5 x 10) Unit Dose per car...

Published: January 14, 2026Recall ID: D-0292-2026Category: drugsCountry: US

Reason for Recall / Hazard

Out of specification for dissolution.

Product Description & Identification

Rosuvastatin Tablets, USP, 10 mg, Rx Only, 50 Tablets (5 x 10) Unit Dose per carton, Manufactured for: AvKARE, Pulaski, TN 38478. NDC: 50268-709-15

Affected Products

Rosuvastatin Tablets, USP, 10 mg, Rx Only, 50 Tablets (5 x 10) Unit Dose per carton, Manufactured for: AvKARE, Pulaski, TN 38478. NDC: 50268-709-15

Additional Source Details

FieldValue
CityPulaski
StateTN
Openfda › Unii83MVU38M7Q
Openfda › RouteORAL
Openfda › Rxcui › 1859419
Openfda › Rxcui › 2859747
Openfda › Rxcui › 3859751
Openfda › Spl id39ff0f38-7c7a-4ce1-e063-6394a90aa663
Openfda › Brand nameROSUVASTATIN
Openfda › Spl set id7cd6ae8d-aa67-60db-e053-2991aa0a0ede
Openfda › Package ndc › 150268-709-11
Openfda › Package ndc › 250268-709-15
Openfda › Package ndc › 350268-710-11
Openfda › Package ndc › 450268-710-15
Openfda › Package ndc › 550268-711-11
Openfda › Package ndc › 650268-711-15
Openfda › Product ndc › 150268-709
Openfda › Product ndc › 250268-710
Openfda › Product ndc › 350268-711
Openfda › Generic nameROSUVASTATIN
Openfda › Product typeHUMAN PRESCRIPTION DRUG
Openfda › Substance nameROSUVASTATIN CALCIUM
Openfda › Manufacturer nameAvPAK
Openfda › Application numberANDA207616
Openfda › Original packager product ndc › 131722-883
Openfda › Original packager product ndc › 231722-884
Openfda › Original packager product ndc › 331722-885
Event id98246
Address 1615 N 1st St
Code infoLot #49124, Exp Date 12/31/2026
Postal code38478-2403
Report date20260114
Product typeDrugs
Product quantity7,991 5x10 cartons
Reason for recallOut of specification for dissolution.
Voluntary mandatedVoluntary: Firm initiated
Recall initiation date20251231
Initial firm notificationLetter
Center classification date20260120

Overview

  • Recalling FirmAvKARE
  • StatusOngoing
  • Risk LevelClass II
  • DistributionNationwide in the USA
Official Agency Alert